Low-risk MDS: non-transplant therapeutic approach

Moshe Mittelman, Tel Aviv Sourasky Medical Center
2021 Cellular Therapy and Transplantation  
A significant progress has been made over the last couple of decades in understanding the biology and treatment of myelodysplastic syndromes. Based on several parameters (% blasts, cytogenteics, number of affected lineages) the patients are classified as having a lower-risk (LR) or higher risk disease. Here, we will focus on LR-MDS. The patients with LR-MDS are treated with RBC transfusions as needed, with or without erythroid stimulating agents. Luspatercept, an activin analogue, is a
more » ... e second line agent. Among the investigational agents in this field we can mention ruxodustat (a HIF inhibitor) and imetelstat, a telomerase inhibitor. Treatment of thrombocytopenia remain challenging and an open question.
doi:10.18620/ctt-1866-8836-2021-10-2-7-16 fatcat:jylnaeo6qfd7jkg7b2zjvlub4m